Cancer Research Technology
Log in Register
Menu

K562 AZQR Cell Line

Info

Catalogue Number 153252
Parental Line K562
Host Human
Tissue Lymphatic Tissue
Disease Keywords Human caucasian chronic myelogenous leukemia (drug resistant)
Model Tumour line
Relevance The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
Production Details The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone).
Conditional No
Research Area Cancer, Drug Discovery & Development
Growth/Phenotype Keywords Suspension
Recommended Growing Conditions Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
Cellosaurus ID CVCL_2967

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.

Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.

Europe PMC ID: 7646550


Add a reference

References: 2 entries

Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.

Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor